Internal Medicine, Endocrinology, Diabetes, & Metabolism · New Haven, CT
NPI
1659417889
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
200 Orchard St, Ste 207
New Haven, CT, 06511
Phone (203) 776-6644
Groups this clinician bills Medicare through
Medicare paid, 2024
$271K
10,202 services
Medicare patients, 2024
656
Average age 75
Drug cost, 2024
$5.4M
12,566 prescriptions
Company payments, 2025
$47K
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Philip A Goldberg was code J0897 (injection, denosumab, 1 mg), 8,040 times for 78 patients. In total Philip A Goldberg billed 10,202 services in 26 codes, and Medicare paid $271K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-11-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 8,040 | 78 | $20.58 | $165K |
| 99214 Office E&M - Established | Office | 682 | 486 | $98.27 | $67K |
| 83036 Blood Count | Office | 181 | 134 | $9.52 | $1,723 |
| 96372 Injection Administration | Office | 157 | 84 | $11.13 | $1,747 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 122 | 107 | $13.77 | $1,679 |
| 99213 Office E&M - Established | Office | 91 | 88 | $67.93 | $6,181 |
| 76536 Ultrasound - Nonspecific | Office | 88 | 87 | $91.93 | $8,090 |
| 99212 Office E&M - Established | Office | 73 | 57 | $43.54 | $3,178 |
| 99204 Office E&M - New | Office | 41 | 41 | $122.00 | $5,002 |
| 99232 Hospital E&M - Subsequent | Facility | 40 | 16 | $63.81 | $2,552 |
| 95251 Test - Miscellaneous | Office | 18 | 13 | $27.53 | $496 |
| 99222 Hospital E&M - Initial | Facility | 13 | 13 | $103.64 | $1,347 |
By year: 2022 $355K for 20,372 services; 2023 $301K for 13,697 services; 2024 $271K for 10,202 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 181 | 134 | $9.52 | $1,723 |
Medicare prescription drug claims, 2024
In 2024, the drug Philip A Goldberg prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,375 prescriptions and refills. In total Philip A Goldberg wrote 12,566 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,375 | 3,757 | 394 | $15K |
| Ozempic Semaglutide | 655 | 1,349 | 194 | $1.3M |
| Metformin Hcl Er Metformin Hcl | 639 | 1,789 | 199 | $8,012 |
| Rosuvastatin Calcium Generic | 514 | 1,431 | 153 | $6,886 |
| Metformin Hcl Generic | 487 | 1,232 | 137 | $5,784 |
| Synthroid Levothyroxine Sodium | 477 | 1,387 | 135 | $53K |
| Jardiance Empagliflozin | 471 | 1,246 | 164 | $721K |
| Atorvastatin Calcium Generic | 412 | 1,160 | 124 | $4,144 |
| Unithroid Levothyroxine Sodium | 332 | 962 | 96 | $14K |
| Glimepiride Generic | 281 | 763 | 85 | $2,654 |
| Losartan Potassium Generic | 278 | 776 | 84 | $3,007 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 274 | 743 | 114 | $30K |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 268 | 713 | 114 | $31K |
| Mounjaro Tirzepatide | 265 | 491 | 90 | $533K |
| Lisinopril Generic | 244 | 707 | 77 | $1,974 |
Brand drugs: 5,120 claims; generic drugs: 6,655 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Philip A Goldberg $47K ($47K in general payments such as food, travel and fees) from 31 companies. The largest payer was Novo Nordisk Inc with $20K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 32 | $20K |
| Lilly USA, LLC LLY | 37 | $17K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 19 | $4,188 |
| Corcept Therapeutics CORT | 7 | $3,253 |
| Amgen Inc. AMGN | 16 | $428 |
| Ascendis Pharma Endocrinology Inc ASND | 11 | $350 |
| Radius Health, Inc. | 8 | $248 |
| Abbott Laboratories ABT | 8 | $189 |
| Insulet Corporation PODD | 12 | $181 |
| Tandem Diabetes Care, Inc. TNDM | 4 | $174 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.